Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sedation - Overview

Sedation - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Sedation - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sedation - Companies Involved in Therapeutics Development

Drawbridge Pharmaceuticals Pty Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Paion AG

Sedation - Drug Profiles

alphaxalone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EL-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HR-7056 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SERx-480 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GABA-A for Sedation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XK-568b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sedation - Dormant Projects

Sedation - Discontinued Products

Sedation - Product Development Milestones

Featured News & Press Releases

Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required

Oct 18, 2017: Remimazolam phase III Broncoscopy data to be presented at the Chest Annual Meeting 2017

Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU

Jun 28, 2017: Paion reports positive headline data in U.S. Phase III trial with Remimazolam for procedural sedation undergoing Bronchoscopy

Mar 28, 2017: Paion successfully completes patient recruitment in U.S. Phase III study with Remimazolam for procedural sedation during Bronchoscopy

Mar 27, 2017: Paion reports positive headline data in U.S. Clinical safety trial of Remimazolam in high-risk patients undergoing colonoscopy

Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting

Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting

Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China

Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy

Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy

Feb 12, 2016: Paion: US-Patent & Trademark Office Grants Substance Patent For Remimazolam Besylate

Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment

Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy

Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority PMDA About Production Of Remimazolam For Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Sedation - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sedation - Pipeline Review, H1 2019, provides an overview of the Sedation (Central Nervous System) pipeline landscape.

Sedation is the depression of irritability or agitation. Symptoms include talk slowly and may slur their speech, unable to concentrate, feel dizzy, slow breathing, heart rate, blood pressure will be lower. Treatment includes barbiturates and benzodiazepines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sedation - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Sedation (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sedation (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Sedation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Preclinical stages are 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sedation (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sedation (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Sedation (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sedation (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sedation (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sedation (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sedation (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sedation (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.